Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

PathAI Launches MET Predict on AISight to Enhance NSCLC Assessments

PathAI

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the launch of MET Predict † on the AISight Ⓡ † Image management system (IMS). MET Predict is an AI-powered algorithm designed to help pathologists identify non-small cell lung cancer (NSCLC) tumors that may be more likely to have MET exon 14 skipping (METex14) or MET amplification, directly from an H&E whole slide image. NSCLC accounts for approximately 85% of lung cancers 1, with 3–4% of these cases involving METex14 2. Today, approved targeted therapies are available for patients with NSCLC who harbor METex14 mutations. Additionally, MET amplification occurs in 1–6% of NSCLC cases 3 and is emerging as a potential biomarker in lung cancer. Traditional molecular testing for MET alterations such as exon 14 skipping or amplification is often hindered by high costs, time- and tissue-consuming procedures, and the need for specialized equipment and trained personnel. These factors limit its accessibility and scalability, prompting the need for more efficient and cost-effective methods to assess MET alterations. “The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.” MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies >90% of MET altered tumors while additionally providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low. With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. †:MET Predict and AISight are for Research Use Only. Not for use in diagnostic procedures. References: 1 American Cancer Society. Key Statistics for Lung Cancer. https://www.cancer.org/cancer/lung-cancer/about/what-is.html 2 Frampton, G. M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer discovery, 5(8), 850-859. 3 Wolf J., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. PMID: 32877583 About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions, dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 10, 2024 10:00 AM Eastern Daylight Time

Image

Brand Engagement Network (NASDAQ: BNAI) Expands Global Footprint As It Secures $5.9M in Private Placement Financing And Enters $50M Standby Equity Purchase Agreement

Benzinga

By Anthony Termini, Benzinga Brand Engagement Network (NASDAQ: BNAI) (BEN), which creates artificial intelligence (AI) solutions for consumer engagement using human-like avatars as the interface to communicate with customers, hit multiple milestones recently Early in September, the company entered into an agreement with IntelliTek Health. IntelliTek Health is a subsidiary of SmarTek21 and creates solutions for virtual assistants that interact with medical patients. It develops clinical and patient-facing tools and focuses exclusively on bringing AI-enabled productivity and services to the healthcare industry. What The IntelliTek Deal Means For BEN The agreement grants BEN a worldwide license to provide AI-driven solutions to support healthcare operations and optimize patient engagement throughout the United States, Australia, New Zealand, India and Europe. Together, BEN and IntelliTek will offer a suite of AI-driven healthcare solutions to support and execute a broad range of tasks and operations that serve both medical professionals and patients. The agreement is intended to seek synergies in the strengths and solutions of both companies. Brand Engagement Network will combine its Healthcare AI Assistant, Sandy – which serves as a direct interface resource for patients – with IntelliTek’s Personal Virtual Assistant (PVA). Sandy can help patients schedule appointments and obtain up-to-date information on prescription drugs. The IntelliTek PVA is part of a collaboration with Samsung Mobile Solutions and other leading U.S. and multinational telecommunications companies. The deal also combines BEN’s AI technology with IntelliTek’s Clinical Virtual Assistant (CVA). The CVA is specifically designed for clinical teams looking to reduce their administrative burden. BEN reports that it has been shown to improve administrative efficiency by up to 50%, creating the opportunity to improve patient throughput by up to 17%. Another solution rolled into the agreement is IntelliTek’s hands-free and voice-enabled Document Search AI. This device-agnostic tool can quickly and securely search for and retrieve specific medical information in real time from many different document formats sourced from a wide variety of different repositories. Martyn Molnar, Chief Executive of Products at Intellitek Health, says that the “cooperation with BEN will enable both companies to offer a comprehensive suite of AI solutions for the healthcare industry, which is experiencing critical challenges surrounding workforce and resource availability.” “We’re proud to have found a like-minded ally in IntelliTek, as we both strive to elevate patient experiences and healthcare professional productivity with innovative AI technology,” added Paul Chang, BEN’s CEO. The two executives believe that together the platforms can serve as an end-to-end suite of solutions that offers continuous support to improve healthcare access and outcomes. They believe the collaboration will help each company broaden its customer base. It is expected that the agreement will expand the reach of both companies’ solutions to a larger number of healthcare providers and patients and increase access to life-saving AI technology. IntelliTek delivers highly curated products that automate over 2 billion interactions reaching more than 600 million global users, reports the company. The company and its parent, SmarTek21, ensure seamless connectivity of more than 100 pre-built integrations to support AI-driven solutions. Together they provide intelligent workflow automation across healthcare, telecommunications, aviation, finance and global eCommerce platforms. The healthcare industry represents one of BEN’s primary target markets. The company’s full-stack platform includes front-end, middleware and back-end functionality through scalable, customizable solutions that it says are fully optimized to deliver superior customer experiences, productivity and performance. New Financing Transactions Prior to the IntelliTek Health announcement, BEN completed two investment transactions that provide the company with increased financial flexibility and access to capital to support its ongoing strategic growth initiatives. In August, BEN closed a $5.9 million private placement, which will provide funding to the company on a monthly basis through the first quarter of 2025. The investment was supported by a group of BEN’s existing stockholders, who agreed to purchase nearly 1.2 million shares of common stock. The transaction was consummated at a price per share that was materially above the trading price of the company’s common stock at the time. For each share purchased, investors received an additional share of common stock from certain other existing stockholders. In exchange for transferring those shares, certain transferring stockholders received an aggregate of 960,000 warrants to purchase shares of BEN’s common stock at $5.00 per share. Concurrent with the private placement, BEN also entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The SEPA provides BEN with the ability, but not the obligation, to cause Yorkville to purchase up to the aggregate amount of $50 million of BEN common stock. The SEPA is intended to provide BEN with access to capital on an as-needed basis to fund its business plan as it seeks to execute its growth and revenue strategies. The SEPA cannot be used until a registration statement is declared effective by the Securities and Exchange Commission. These two transactions are intended to help the company expand market validation and scale production of its human-like conversational AI assistants. For more information about BEN, please visit www.beninc.ai. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:55 AM Eastern Daylight Time

Image

Syntekabio Appoints Joonhyuk Choi, Former Target Health CEO, as Head of US Operations

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. Joonhyuk brings over 25 years of extensive experience in the pharmaceutical industry, underpinned by his academic background in electrical and computer engineering from Rutgers University in New Jersey. His prominent career is distinguished by a strong track record in developing clinical trial software, navigating the US FDA’s drug and medical device approval processes, managing clinical trials, and leading business development success. Prior to joining Syntekabio, Joonhyuk served as CEO of Target Health, a US-based contract research organization (CRO). There, he played a pivotal role in clinical operations and drove business development, spearheading sales and marketing teams while overseeing the development and maintenance of validated software solutions for clinical trials and data management for over two decades. Syntekabio anticipates that Joonhyuk, with his deep understanding of the drug development process from AI-driven drug discovery and clinical trials to drug approvals as well as business development, coupled with his extensive knowledge of the US market, will significantly enhance the company’s strategic partnership and revenue-generating initiatives. “I am honored to join Syntekabio at such a pivotal moment in the company’s journey,” said Joonhyuk Choi, newly appointed Head of US Operations. “I am committed to leveraging strategies tailored to the unique dynamics of the US pharma and biotech market to enhance the global reach and impact of Syntekabio’s AI drug discovery platform.” Jongsun Jung, PhD, CEO of Syntekabio, remarked, “With Joonhyuk’s appointment, Syntekabio is now strategically positioned to collaborate with potential partners across the entire drug development spectrum, from AI-driven candidate screening to clinical trials. His extensive expertise and experience in the US market will be crucial in driving our global expansion and enhancing our competitiveness, positioning us for achieving sustained business success.” About SyntekabioSyntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries – US & Europe - Laurie Doyle MC Services AG +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 10, 2024 08:00 AM Eastern Daylight Time

Flash Secures $85 Million to Back Special Purpose Vehicle to Propel Growth and Provide Flexible Payment Options

Flash

Flash, the industry-leading end-to-end parking technology platform, today announced that it has closed on $85 million in debt financing for a newly formed special purpose vehicle (“SPV”) to accelerate platform adoption and offer Flash clients an expanded range of flexible payment options. The debt capital, which can be increased up to $100 million, was provided by Vantage Infrastructure (“Vantage”), a leading independent specialist infrastructure credit fund. “Asset owners and operators have a myriad of budgetary and deployment preferences – the payment options we can now extend through the SPV will allow customers to join the Flash platform on terms that work best for them," said Chris Donus, President of Flash. “Innovation in payment options is as critical as platform innovation in pursuit of our vision for the parking industry’s transformation in light of the scale and momentum we're on pace to achieve." Flash’s payment options allow clients to select amongst flexible monthly payment plans that suit their budgets, regardless of scale, asset type, or configuration. This includes EV charging infrastructure and other advanced parking technologies offered by Flash. Flash anticipates extending the SPV structure and partnership with Vantage in future financings. ”We’re pleased to support Flash with a tailored financing solution that enables their team to continue to meet and exceed their clients’ need for better transport related infrastructure,” said Nick Cleary, Senior Partner at Vantage. “This is a great example of the opportunity to upgrade and transform proven traditional infrastructure that saves time and costs for drivers and help build out the EV charging network.” Evercore acted as Flash’s exclusive financial advisor, and Cadwalader, Wickersham & Taft LLP provided legal counsel to Flash. Steptoe LLP acted as counsel to Vantage. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. About Vantage Infrastructure Vantage Infrastructure is an independent infrastructure specialist manager committed to delivering sustainable investment solutions with an equity and debt infrastructure investment portfolio of over US $4 billion invested in infrastructure assets across Europe, North America, and Australia on behalf of global clients. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 09, 2024 09:00 AM Central Daylight Time

Syntekabio to Highlight its Cutting-edge AI-driven Discovery Solutions at BioTechX

Syntekabio, Inc.

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its participation at BioTechX USA, being held September 17-18, 2024 in Philadelphia, PA. Syntekabio is the Title Sponsor for the event and will give a keynote address and in-depth talk on its AI-driven solutions, as well as host a booth. “We look forward to meeting with potential clients at BioTechX and discussing how our AI-driven technologies can improve and accelerate their R&D activities,” said Jongsun Jung, PhD, CEO of Syntekabio. “We recently announced our ‘Develop Now, Pay Later’ offer that enables clients to test the validity of a target protein of interest without incurring any upfront costs. In addition to identifying potential hits and optimizing small molecule leads, we also have strong capabilities in antibody and cancer neoantigen discovery. We are excited to have the opportunity to highlight these technologies at the conference.” Meet us at BioTechX USA! Syntekabio has several activities planned at the conference. Schedule a meeting by clicking here or stop by our booth (#401) to meet the team and learn how our innovative AI-driven solutions can help solve your current pipeline challenges. Don’t miss out on the latest insights in AI presented in our talks! Tuesday, September 17 th 9:20 AM - Keynote presentation Addressing Data Scarcity in D rug Discovery with Physics-based AI Models Jonathan Witztum, PhD, CTO, Syntekabio USA 5:05 PM – AI in drug discovery presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio Recently announced Develop Now, Pay Later offer – drug discovery with no upfront fees Syntekabio’s Develop Now, Pay Later model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher ® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates. The client only pays for the work once the agreed upon validated results are obtained. For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here. Additional powerful tools enable novel antibody and cancer neoantigen prediction Additionally, the company will highlight its in silico biologics platforms, Neo-ARS TM and Ab-ARS TM, which enable personalized or universal neoantigen cancer vaccine and novel antibody drug prediction, respectively. These cutting-edge solutions address complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics. Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process. About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates. Contact Details Media inquiries US & Europe - MC Services AG Laurie Doyle / Dr. Cora Kaiser +1 339-832-0752 syntekabio@mc-services.eu Company Website http://www.syntekabio.com/

September 06, 2024 08:30 AM Eastern Daylight Time

PayMedix/TempoPay Names David Kinsey Vice President of Sales

PayMedix/TempoPay

PayMedix/TempoPay announced today the appointment of David Kinsey as Vice President of Sales. Kinsey joins during a period of accelerated growth for PayMedix/TempoPay, which delivers innovative healthcare payment solutions that provide interest-free financing to employees for healthcare services, no matter their credit histories. Kinsey brings an extensive background in the healthcare and employee benefits industry. In his new role, Kinsey will lead sales initiatives, focused on driving growth of the PayMedix/TempoPay solution and building strategic relationships across the healthcare industry with a specific focus on the Southeast region. “As more health systems, employers, and benefits administrators across the country continue to look for ways to lower costs and provide affordable access to healthcare for employees, we're seeing increased interest in our flexible financing and payments solutions," said Tom Policelli, CEO of PayMedix/TempoPay. "David's extensive knowledge of healthcare sales and the employee benefits industry will help us increase our reach and ability to serve providers and employers looking for alternative healthcare payment solutions. We are excited to welcome him to our team." Before his current role, Kinsey was an Executive Director at Aetna. He led the Healthcare Business Solutions team to achieve 60% growth over five years by directing enterprise sales, retention, and membership growth strategy. Kinsey was awarded Aetna's Chairman's Leadership Award for his leadership and collaboration. Kinsey’s prior roles at Aetna included working with employer groups and consultants on innovative employee benefits strategies and plan administration. Prior to Aetna, he was a Senior Client Manager at Cigna Healthcare, where he was awarded the Gold Circle for top sales results. He earned his BBA in Finance from Stetson University. "The PayMedix/TempoPay solution is a game-changer, offering a straightforward and effective approach to tackling the demanding issue of high out-of-pocket healthcare costs," said Kinsey. "I look forward to working with the team to expand our reach and bring employers a financial safety net for their employees that ultimately improves retention and reduces absenteeism.” “Having worked with David previously, I am confident in his ability to help employers, PEOs, health plans and network builders see the value in our solution,” said Brian Marsella, President, PayMedix/TempoPay. “By ensuring individuals have access to financial resources to get care when they need versus when they think they can afford it, we can break the cycle of care avoidance, which historically has led to sicker patients entering the system, worse outcomes and increased costs.” About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay VisaÂ® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. Contact Details Brodeur Partners Sam LeCompte +1 603-660-9407 slecompte@brodeur.com Company Website https://paymedix.com

September 05, 2024 10:00 AM Eastern Daylight Time

The Technology Powering Aeva's (NYSE: AEVA) Vision For A Safer Autonomous Future And Why It Could Be Game-Changing

Benzinga

By Meg Flippin, Benzinga When it comes to autonomous driving, safety and accuracy are top of mind. For self-driving cars, trucks and trains to become ubiquitous on America’s roads, streets and railways, they must be extremely safe and reliable. The same goes for the robots that will someday deliver everything from food to medicine without human intervention. They have to be able to see everything around them and react in real time to avoid crashes. Technology advances and companies like Aeva Technologies (NYSE: AEVA) are making that a reality. Mountain View, California-based Aeva makes LiDAR sensors for use in vehicles, trucks and trains. The sensors act as eyes, providing 3D views of the surroundings. FMCW, The Technology Enabler For Highway Autonomy What takes Aeva’s sensors to the next level on the safety and reliability fronts is its Frequency Modulated Continuous Wave (FMCW) 4D LiDAR technology, which uses a low-power continuous laser beam to measure range and a fourth dimension of velocity at the same time. Aeva says FMCW unlocks new levels of safety and automation by instantaneously discriminating between moving and non-moving points and knowing the precise velocity of objects in motion. Instant velocity data gives real-time insight into how an object’s position is changing, giving the vehicle’s computer a more accurate picture to help plan its next move. But that’s not all. Aeva’s sensors also have advanced perception capabilities that deliver new features, which the company says are not possible with typical legacy LiDAR sensors, including Ultra resolution and vehicle localization. Ultra resolution provides a camera-like image of the world providing what Aeva Technologies says is up to 20 times the resolution of legacy time-of-flight LiDAR sensors. Image segmentation enables the detection of roadway markings, drivable regions, vegetation, road barriers and road hazards like tire fragments at up to twice the distance of conventional time-of-flight LiDAR sensors. Instant velocity data allows for confident detection and tracking of dynamic objects such as oncoming vehicles and other moving objects at distances up to 500 meters, reports Aeva. Meanwhile the technology’s Vehicle Localization features enable real-time vehicle motion estimation with six degrees of freedom, providing accurate vehicle positioning and navigation, which could be a substitute for other sensors, like IMU or GPS. That provides for safe autonomous navigation in common GPS-denied environments like tunnels and parking structures. Aeva says its FMCW technology provides autonomous vehicles with freedom from interference from sunlight and other LiDAR sensors, elimination of retroreflector blooming and ghosting from highly reflective objects like street signs and roadway markings, as well as a greater ability to see in weather conditions like dust, fog, rain and snow. Importantly, these benefits can allow automated vehicles to safely operate at highway speeds, a feat that has been sought after by major car manufacturers. Overcoming The Limitations With all that safety and technology packed into Aeva’s LiDAR sensors, Aeva is overcoming one of the biggest challenges of self-driving vehicles today: blindspots. Self-driving vehicle algorithms and conventional sensors can have difficulty when the weather is bad, lane markings are not clear or unexpected obstacles are in their way. That can lead to accidents and fatalities. Reacting in real-time is the goal and Aeva delivers that with its LiDAR sensors. The company’s FMCW LiDAR sensors can also enable self-driving cars and trucks to achieve highway speeds safely. It's something that has eluded the industry so far, with many self-driving vehicles achieving top speeds of 35 to 45 MPH. For the trucking industry to move to autonomous vehicles, it has to be able to sustain highway speeds safely. Achieving that can someday address the labor shortages the heavy truck industry faces. Finding drivers who want to spend most of their time on the road and away from family for three to four-week clips is harder to come by. Autonomous trucks that can run all day and all night can help fill that gap. It’s why Daimler Truck AG is using Aeva’s sensors in its Class 8 Freightliner Cascadia autonomous truck platform. Daimler Truck intends to integrate the LiDAR sensors directly into its production process, making it easy for customers to buy autonomous-ready trucks directly from its manufacturing plants. Daimler Truck said it chose Aeva’s LiDAR sensors because of its ability to provide enhanced safety and control. “Daimler Truck is committed to leading the industry’s advancement toward autonomous trucks. Selecting the right LiDAR technology is a crucial strategic decision to safely deploy autonomous trucks on the road,” said Joanna Buttler, Head of Global Autonomous Technology Group at Daimler Truck. “We are convinced that Aeva with its cutting-edge and reliable technology is the right production partner for LiDAR sensors and has the manufacturing capabilities to scale along with us.” The world is moving toward autonomous vehicles but for them to become ubiquitous safety can’t be a question. That’s where companies like Aeva Technologies come in. Its advanced next-generation LiDAR sensors can react in real-time, potentially taking autonomous driving to the next level. Learn more about Aeva Technologies Inc. by checking out its investors deck here. Featured photo by Chris Bair on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:55 AM Eastern Daylight Time

Image

$10K Up For Grabs For The Top 100 Traders In BullRush’s Upcoming Trading Event

Benzinga

By James Blacker, Benzinga Think you’ve got what it takes to take home the prize? Sign up for BullRush’s Crypto, Forex and CFD trading competition here. Gamified trading platform BullRush is offering a unique opportunity for anyone interested in learning how to trade while making money. Starting from its September 9 launch, the company is running a fantasy trading game with a total prize pool of $10,000 to be awarded to the top 100 traders in the competition. The trading competition will feature any of the following assets: Crypto, Forex and CFDs. Whether you are an experienced or beginner trader, BullRush’s launch event could be your chance to level up your skills and potentially walk away with a cash prize. Master The Art Of Trading With BullRush BullRush's trading platform offers skill-based games, which, much like chess, require participants to master various tools and strategies to outwit their opponents and win. The upcoming tournament allows traders to practice new skills, strategies and ideas in a demo account without using real money. This focus on strategy and skill makes BullRush a suitable learning ground for traders of all experience levels. Fantasy trading in a demo account has many benefits, such as the ability to test and refine your trading strategies, experiment with different styles as well as try out different asset classes. Furthermore, with simulated trading, you can forward-test your strategy in real-time live markets. Trading psychology is a major factor that can be the difference between success and failure in the markets. With no money at stake, fantasy trading lets you practice without the emotional stress and burnouts associated with trading, helping you to develop discipline before you transition your strategies to real-money trading. BullRush Is More Than Just Trading BullRush is not just a trading platform – it's an interactive community where traders can learn, compete and grow together. In addition to the games and tournaments, BullRush also offers trading courses, tutorials and trading analysis. The platform aims to foster a strong community spirit, with traders able to connect, share strategies and learn from one another. Joining The BullRush Community To commemorate its launch on September 9, Bullrush is hosting a launch event, where the best 100 traders in the competition will share a prize pool of $10,000. This fantasy trading game is not just about winning money; it's also about learning to trade effectively while having fun in a dynamic, interactive environment. As the official launch of BullRush approaches, now is the perfect time to get involved. Whether you're looking to test your skills, learn new strategies or simply enjoy the thrill of the game, BullRush offers a unique trading experience. With a $10K prize pool up for grabs, there's never been a better time to join the BullRush community and see what you're capable of. Think you’ve got what it takes to take home the prize? Sign up for BullRush’s Crypto, Forex and CFD trading competition here. Featured photo courtesy of BullRush. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:45 AM Eastern Daylight Time

Image

Crossroads Summit Taps Renowned Historian And Demographer Neil Howe As Panelist For November Event

Benzinga

By Anthony Termini, Benzinga The Crossroads Summit, scheduled to take place Nov. 21-22 in Miami, Florida, is billed as a conference for savvy investors and business leaders. Summit attendees will hear from visionaries in a number of disciplines, from academia to investment research. A central theme will be the role of rapid change in propelling innovations that create opportunity. Neil Howe: Navigating The Era Of Crisis And Renewal One of the visionaries recruited to speak at the Crossroads Summit is Neil Howe, an authority on generational trends. He is an economist and demographer, as well as a historian and sociologist. Howe is a senior associate at the Center for Strategic and International Studies and the Global Aging Institute, both in Washington, D.C. He is the Managing Director of Demography at Hedgeye Risk Management and his human resources and strategic planning consulting firm, LifeCourse Associates, has served hundreds of corporate, government and nonprofit clients. The author of several books on “generational theory”, which argues that history repeats itself in 80 to 100-year cycles, Howe will share his insights on how these turning points impact America's ability to invest in its future. In his latest book, “The Fourth Turning Is Here,” Howe shows that America is currently in the last stage of one of these long cycles. He describes past turnings as “traumatic and transformative” and notes that they “dramatically reshape attitudes, behaviors, and the future of society.” Howe will lead a fireside chat at the Crossroads Summit, sponsored by TradeStation Group, that will delve into what the current stage of these cyclical patterns implies for America’s present and future. Howe Among Many Experts To Speak At The Crossroads Summit More than a dozen speakers, all experts in their respective fields, will address attendees at the Crossroads Summit. Each will focus on how turmoil like what Howe identifies will inspire the innovative solutions that could drive future investment opportunities. The conference is intended to help investors learn how to adjust their investing strategies to focus on future themes such as the end of near-zero interest rates, immigration policy, changes in the domestic workforce and new investable products. Fireside chats and panel discussions are intended to offer attendees investable insights by uncovering the hidden trends and critical developments that are driving world markets and economies. TradeStation Group is the title sponsor of the Crossroads Summit. Ticket packages are available at the Crossroads Summit website. TradeStation Group’s Sponsorship In The Crossroads Summit The Crossroads Summit was created to help business leaders and investors cut through the current clutter of information. Today's leaders are often inundated with so much data that making future projections is more difficult than just a few years ago. Today’s world is facing unprecedented challenges and disruption with advancements in artificial intelligence, political and economic uncertainty, an increase in armed conflict and rapid changes in technologies like cryptocurrency and fintech innovations. The Crossroads Summit is intended to be a catalyst for uncovering investment opportunities. As such, it was a natural fit that a global financial services company like TradeStation Group should present the conference. TradeStation Group aims to offer investors comprehensive market access and high-quality trade execution. The platform provides trading capabilities in stocks, options, mutual funds, and ETFs. TradeStation Group’s sponsorship of the Summit appropriately dovetails its capabilities with the needs of attendees. See how the fourth turning might shape future investments by attending the 2024 Crossroads Summit. Featured photo by Holgi on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:30 AM Eastern Daylight Time

Image

1 ... 16 17 18 19 20 ... 642